Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $714.73M |
| Net Income (Most Recent Fiscal Year) | $145.49M |
| PE Ratio (Current Year Earnings Estimate) | 11.50 |
| PE Ratio (Trailing 12 Months) | 13.00 |
| PEG Ratio (Long Term Growth Estimate) | 0.52 |
| Price to Sales Ratio (Trailing 12 Months) | 2.63 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.71 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.56 |
| Pre-Tax Margin (Trailing 12 Months) | 26.48% |
| Net Margin (Trailing 12 Months) | 20.53% |
| Return on Equity (Trailing 12 Months) | 24.32% |
| Return on Assets (Trailing 12 Months) | 15.92% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.67 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.63 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.22 |
| Inventory Turnover (Trailing 12 Months) | 24.69 |
| Book Value per Share (Most Recent Fiscal Quarter) | $12.55 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.78 |
| Earnings per Share (Most Recent Fiscal Year) | $2.51 |
| Diluted Earnings per Share (Trailing 12 Months) | $2.62 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 57.42M |
| Free Float | 43.87M |
| Market Capitalization | $1.96B |
| Average Volume (Last 20 Days) | 0.72M |
| Beta (Past 60 Months) | 0.82 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 23.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.23% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |